HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio

Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos faces new competition.

By FiercePharma · May 5, 2026 · via FiercePharma
BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
moneyformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
With $97M, Latus pursues a different kind of Huntington’s gene therapy
MoneyBioPharma Dive ↗
With $97M, Latus pursues a different kind of Huntington’s gene therapy
The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enab…
May 4, 2026
Seaport’s $255M Upsized IPO Defies the Big Pharma M&A Pull
MoneyBriefing
Seaport’s $255M Upsized IPO Defies the Big Pharma M&A Pull
Seaport Therapeutics opted for a $255M Nasdaq IPO over an acquisition, underscoring renewed investor appetite …
May 3, 2026
Moderna sees revenue bump from international COVID vaccine sales
MoneyBioPharma Dive ↗
Moderna sees revenue bump from international COVID vaccine sales
The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turna…
May 1, 2026